Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22446404 | 0.81 | MEN1 (0.35) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21882563 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL22174558 | 0.78 | MEN1 (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL22757501 | 0.76 | MEN1 (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL15441 | 0.76 | KDM4E (0.42) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL16646930 | 0.76 | EGFR (0.32) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL15440 | 0.76 | KDM4E (0.42) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL22246044 | 0.76 | KDM4E (0.42) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL21370887 | 0.75 | MEN1 (0.32) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21160710 | 0.75 | CTSK (0.33) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170131278-A1 | METHOD FOR SCREENING INHIBITORS OF RAS | ARAXES PHARMA LLC | 2017-05-11 | — | — | US | disclosed |
| US-20170131278-A1 | METHOD FOR SCREENING INHIBITORS OF RAS | ARAXES PHARMA LLC | 2017-05-11 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | ALDH1A1 2798/4885MEN1 425/4885KMT2A 607/4885 |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | ALDH1A1 3457/4885MEN1 102/4885KMT2A 1188/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3753/4885MEN1 122/4885KMT2A 1296/4885 |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1402/4885MEN1 230/4885KMT2A 2102/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | ALDH1A1 3814/4885MEN1 1672/4885KMT2A 3580/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885MEN1 138/4885KMT2A 850/4885 |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | KRAS, NRAS, HRAS | ALDH1A1 3346/4885MEN1 132/4885KMT2A 718/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885MEN1 138/4885KMT2A 850/4885 |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 2059/4885MEN1 170/4885KMT2A 1250/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | ALDH1A1 4032/4885MEN1 2/4885KMT2A 5/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | ALDH1A1 1577/4885MEN1 872/4885KMT2A 1502/4885 |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3333/4885MEN1 103/4885KMT2A 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.